Nonetheless, in human breast and gastric cancers, GSDMB over-expression is frequently produced by the co-amplification of GSDMB and HER2/NEU within the 17q12-21 region (Saeki et al., 2009; Hergueta-Redondo et al., 2016), and indeed GSDMB upregulation associates with aggressive behavior, resistance to therapy and poor clinical outcome in HER2-positive breast carcinomas (Hergueta-Redondo et al., 2016; Molina-Crespo et al., 2019). The gene discussed is ERBB2; the disease is breast carcinoma.